ESMO 2017 Kidney Cancer

Viewing 1-15 of 15 articles

ESMO 2017: Kidney Cancer Poster Discussion – Invited Discussant

ESMO 2017: Safety and efficacy of Cabozantinib for metastatic renal cell carcinoma: Real world data from an Italian Expanded Access Program

ESMO 2017: SPAZO2 (SOGUG): Validation of the International Metastatic Database Consortium prognostic classification for targeted therapies as 2nd-line after 1st-line pazopanib in metastatic renal cell carcinoma

ESMO 2017: Outcomes of patients with metastatic renal cell carcinoma who were treated with second-line vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI) after first-line immune checkpoint inhibitor therapy

ESMO 2017: Association between biopsychosocial distress and overall survival in patients with metastatic renal cell carcinoma

ESMO 2017: SPAZO2 (SOGUG): Comparative effectiveness of everolimus vs axitinib as second-line after first-line pazopanib in metastatic renal carcinoma

ESMO 2017: Cabozantinib for the treatment of patients with metastatic variant histology renal cell carcinoma: A retrospective study

ESMO 2017: Adjuvant sunitinib in patients with high risk renal cell carcinoma (RCC): Safety and therapy management in S-TRAC trial

ESMO 2017: A Change of Paradigm in First-Line Treatment of Metastatic Renal Cell Carcinoma?

ESMO 2017: IMmotion150: Novel Radiological Endpoints and Updated Data From a Randomized Phase II Trial Investigating Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma

ESMO 2017: Progression-free survival by independent review and updated overall survival results from Alliance A031203 trial (CABOSUN): cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma

ESMO 2017: Phase Ib/II Trial of Interleukin-2 and Nivolumab in Metastatic Clear Cell Renal Cell Cancer

ESMO 2017: CheckMate 214: Efficacy and safety of Nivolumab + Ipilimumab vs Sunitinib for treatment-naïve advanced or metastatic renal cell carcinoma, including IMDC risk and PD-L1 expression subgroups

ESMO 2017: KEYNOTE-564: Phase 3 trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma

ESMO 2017: Pazopanib or Sorafenib + Radium-223 in Metastatic Renal Cell Carcinoma with Bone Metastases